Monoclonal antibody (mAb) drugs are one of the most important categories in the global biopharmaceutical market. It is also the most popular research and development field. Creative Biolabs provides a comprehensive range of customized, high-quality services in mAb development to support the drug industry and related biomedical science research. Based on cytokine receptors, we provide mAb development services to promote the therapy of autoimmune diseases (ADs).
Rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriasis, multiple sclerosis (MS), type-1 diabetes, Crohn's disease (CD), and systemic sclerosis (SS) are common autoimmune diseases. Inflammatory cytokines and chemokines appear to be centrally involved in the pathogenesis of these diseases.
In the presence of the interferon (IFN), local antigen-presenting cells (APCs) produce interleukin (IL)-12 leading to differentiation of differentiation 4 receptors (CD4+) T cells into IFN-secreting T helper type 1 (Th1) cells. A study showed that TNF-α is associated with RA, CD and psoriasis, while interleukin 6 (IL-6) / interleukin 6 receptor (IL-6R) are clinically relevant with RA and CD. Another study showed that IL-21 is a modulator of the adaptive immune response towards self-tissue in diseases such as RA, SLE, MS, and type-1 diabetes.
Fig.1 Interaction between inflammatory cells and cytokine milieu in Taoism. (Liu, 2013)
Traditionally, ADs are treated with immunosuppressive drugs that non-specifically inhibit the immune system. Corticosteroids or cytotoxic drugs are usually needed in the treatment of severe cases. However, these drugs can't control diseases well and may lead to serious complications. mAb can be more directly focused on specific cells (and functions) of the immune system, which leads to new therapeutic strategies.
Based on various steps of the immune system, many biological approaches have been explored for effective regulation to meddle disease progression. At the same time, various monoclonal antibodies have been developed and used to treat multiple autoimmune diseases, such as monoclonal antibodies targeting IL-1, IL-2, IL-6, IL-17, IL-12, and IL-23.
To treating autoimmune diseases, the development of drugs targeting cytokines has made promising progress. However, drugs targeting cytokine receptors need to be further developed. With rich experience in the development of mAb, Creative Biolabs provides you one-stop antibody development and characterization services, including but not limited to:
Based on cytokine receptors, Creative Biolabs provides mAb development services to advance the therapy of autoimmune diseases. If you want to know more details, you can contact us.
For Research Use Only | Not For Clinical Use